Navigating new frontiers: Ways to find space in the future RA market
Overview
Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).
The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.
Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.
Analysis of Therapy Watch data, a real-time' syndicated market tracking tool from Research Partnership, shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.
This pharmaphorum webinar, held in conjunction with Research Partnership, will use the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.
Focus
The webinar was held on Thursday 21st March from 15:00-16:00 GMT and provided an opportunity to interact with the panel about how companies could best harness the potential of this increasingly complex, but highly rewarding, market.
Topics covered included:
- The European RA market
- Current status and market situation of JAK inhibitors (key EU5 countries)
- Uptake curve of JAKs compared to other new entrants and biosimilars
- The patient profile and unmet needs in RA
- Profile of physicians prescribing JAKS
- Country differences
- The future of new classes of JAK inhibitors
To view the debate on demand, please click here or on the button above or below.
Our Panel
Helen Parfitt, Director, Head of Therapy Watch Research Partnership
Helen is Head of Therapy Watch, Research Partnership’s real-time’ syndicated market tracking tool. She has over 20 years’ experience in the healthcare industry including client-side roles in sales, training and pharmaceutical product management and agency roles in commercial effectiveness and globally syndicated data. Helen oversees the Therapy Watch Rheumatoid Arthritis study and has extensive knowledge in this field. Her research experience spans all markets and covers a wide range of therapy areas including autoimmune, allergy, respiratory, dermatology, cardiovascular and hyperlipidaemia.
Mariel Metcalfe, Head of Living With, Research Partnership
Mariel is Head of Living With, Research Partnership's syndicated patient report series. She has over 10 years’ experience in healthcare and has worked in a wide variety of therapy areas. Mariel has extensive knowledge of Rheumatoid Arthritis having conducted patient studies in the US, EU, Canada and Japan and has delved deep into attitudes towards JAK inhibitors. She has vast experience managing large scale, international projects in both qualitative and quantitative spheres. Mariel is passionate about championing the patient and regularly authors articles on patient insights in various online publications.
Mark Hollis, Associate Director, Research Partnership
Mark is an Associate Director in the Therapy Watch team. He is involved in the Therapy Watch Rheumatoid Arthritis study, conducted in the key EU5 countries (France, Germany, Italy, Spain and the UK) and also has a special interest in psoriasis and migraine. Mark has over 10 years’ experience in healthcare analytics across numerous fields including forecasting, biosimilars competitive intelligence, strategic analysis, and pricing and reimbursement.
Dominic Tyer, Creative Director, pharmaphorum (moderator)
Dominic Tyer is a trained journalist and editor with 19 years of pharmaceutical and healthcare publishing experience. He serves as a contributing editor at pharmaphorum media, which facilitates productive engagement for pharma, bringing healthcare together to drive medical innovation. He is also creative director at the company’s specialist healthcare content consultancy, pharmaphorum connect.
